Advertisement

Annals of Hematology

, Volume 98, Issue 10, pp 2339–2346 | Cite as

CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients

  • Massimiliano BonifacioEmail author
  • Rachele Montemezzi
  • Alice Parisi
  • Giovanna De Matteis
  • Roberta Bertorelle
  • Luigi Scaffidi
  • Cinzia Candiotto
  • Giuseppe Lippi
  • Alberto Zamò
  • Marco Chilosi
  • Giovanni Pizzolo
  • Aldo Scarpa
  • Mauro Krampera
Original Article
  • 90 Downloads

Abstract

Calreticulin (CALR) mutations are detected in the majority of JAK2 wild type patients with essential thrombocythemia (ET). Unlike JAK2V617F and MPL point mutations, CALR mutations are highly heterogeneous, with several types of indels being reported so far. CAL2 is a monoclonal antibody specifically recognizing the C-neoterminal peptide derived from all the frameshift mutations of CALR. We retrospectively analysed 172 ET patients diagnosed at our Institution from 1980 to 2015. In JAK2V617F- and MPLW515K/L-wild type patients CALR mutations were searched on peripheral blood and CAL2 immunostaining was performed on bone marrow. In addition, bone marrow biopsies were histologically reviewed for megakaryocytic features. Thirty-one patients (18%) were CALR-mutated. Concordance between molecular and immunohistological detection of CALR mutations was near complete, albeit a single patient was found to be positive by molecular tests only. Two patterns were defined in CAL2-positive bone marrow samples, characterized by staining of almost only megakaryocytes (pattern A: 41%) or staining of megakaryocytes and ≥ 2% small non megakaryocytic elements (pattern B: 59%), at least partially being myeloid precursors. Pattern B biopsies had higher cellularity and number of megakaryocytes compared to pattern A samples. In this series, CAL2 allowed rapid and cost-efficient identification of CALR-mutated ET patients. The biological significance of different staining pattern should be confirmed in wider and independent series.

Keywords

Essential thrombocythemia Calreticulin CAL2 Driver mutations Diagnostic tools 

Notes

Authorship

M.B. and M.C. designed the study; M.B., R.M. and L.S. treated patients, analysed the data and wrote the manuscript; A.P. and A.Z. performed histopathological tests and analysed the data; G.D.M., R.B. and C.C. performed molecular biology tests; G.L., G.P., A.S. and M.K. critically revised the manuscript. All authors have read and approved the final version.

Compliance with ethical standards

Conflict of interest

M. Bonifacio declares research funding from Novartis and received speaker bureau and advisory board honorarium from Amgen, Bristol-Myers Squibb, Incyte, Novartis and Pfizer, outside the present study. All the other authors declare no competing financial interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

277_2019_3741_MOESM1_ESM.docx (95 kb)
ESM 1 (DOCX 94 kb)

References

  1. 1.
    Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M (2004) Life expectancy and prognostic factors for survival in patients with polycytemia vera and essential thrombocytemia. Am J Med 117(10):755–761.  https://doi.org/10.1016/j.amjmed.2004.06.032 CrossRefGoogle Scholar
  2. 2.
    Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390.  https://doi.org/10.1056/NEJMoa1311347 CrossRefGoogle Scholar
  3. 3.
    Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405.  https://doi.org/10.1056/NEJMoa1312542 CrossRefGoogle Scholar
  4. 4.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405.  https://doi.org/10.1182/blood-2016-03-643544 CrossRefGoogle Scholar
  5. 5.
    Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NCC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'Antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M, on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544–1551.  https://doi.org/10.1182/blood-2013-11-539098 CrossRefGoogle Scholar
  6. 6.
    Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ESG, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29(23):3179–3184.  https://doi.org/10.1200/JCO.2010.34.5298 CrossRefGoogle Scholar
  7. 7.
    Stein H, Bob R, Dürkpo H, Erck C, Kämpfe D, Kvasnicka HM et al (2016) A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies. Leukemia 30(1):131–135.  https://doi.org/10.1038/leu.2015.192 CrossRefGoogle Scholar
  8. 8.
    Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M et al (2014) Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia 28(9):1811–1818.  https://doi.org/10.1038/leu.2014.100 CrossRefGoogle Scholar
  9. 9.
    Andrici J, Farzin M, Clarkson A, Sioson L, Sheen A, Watson N, Toon CW, Koleth M, Stevenson W, Gill AJ (2016) Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms. Pathology 48(4):319–324.  https://doi.org/10.1016/j.pathol.2016.03.002 CrossRefGoogle Scholar
  10. 10.
    Nomani L, Bodo J, Zhao X, Durkin L, Loghavi S, Hsi ED (2016) CAL2 immunohistochemical staining accurately identifies CALR mutations in myeloproliferative neoplasms. Am J Clin Pathol 146(4):431–438.  https://doi.org/10.1093/ajcp/aqw135 CrossRefGoogle Scholar
  11. 11.
    Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437–438.  https://doi.org/10.1038/sj.leu.2404914 CrossRefGoogle Scholar
  12. 12.
    Veneri D, Capuzzo E, De Matteis G, Franchini M, Baritono E, Benati M et al (2009) Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. Blood Transfus 7(3):204–209.  https://doi.org/10.2450/2009.0070-08 Google Scholar
  13. 13.
    Kanellis G, Roncador G, Arribas A, Mollejo M, Montes-Moreno S, Maestre L, Campos-Martin Y, Ríos Gonzalez JL, Martinez-Torrecuadrada JL, Sanchez-Verde L, Pajares R, Cigudosa JC, Martin MC, Piris MA (2009) Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia 23(10):1847–1857.  https://doi.org/10.1038/leu.2009.108 CrossRefGoogle Scholar
  14. 14.
    Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, Kremer M, Schmitt-Graeff A, Schwarz S, Thiele J, Werner M, Stein H (2016) Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis – a consensus-based study. Histopathology 68(6):905–915.  https://doi.org/10.1111/his.12871 CrossRefGoogle Scholar
  15. 15.
    R Core Team (2015) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/. Accessed 25 June 2019
  16. 16.
    Tefferi A, Pardanani A (2015) Myeloproliferative neoplasms. A contemporary review. JAMA Oncol 1(1):97–105.  https://doi.org/10.1001/jamaoncol.2015.89 CrossRefGoogle Scholar
  17. 17.
    Jones AV, Ward D, Lyon M, Leung W, Callaway A, Chase A, Dent CL, White HE, Drexler HG, Nangalia J, Mattocks C, Cross NCP (2015) Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res 39(1):82–87.  https://doi.org/10.1016/j.leukres.2014.11.019 CrossRefGoogle Scholar
  18. 18.
    Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F (2014) Type 1 vs type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 89(8):E121–E124.  https://doi.org/10.1002/ajh.23743 CrossRefGoogle Scholar
  19. 19.
    Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O (2015) Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocythemia: relevance for disease evolution. Leukemia 29(1):249–252.  https://doi.org/10.1038/leu.2014.270 CrossRefGoogle Scholar
  20. 20.
    Riera L, Osella-Abate S, Benevolo G, Beggiato E, Ferrero S, Pich A, Francia di Celle P (2016) Novel CALR somatic mutations in essential thrombocythemia. Br J Haematol 173(5):797–801.  https://doi.org/10.1111/bjh.13638 CrossRefGoogle Scholar
  21. 21.
    Butylin P, Matyuhina N, Lisina E, Siordia N, Senderova O, Lomaia E, Zaritskey A (2016) Calreticulin mutations variants of ET and PMF patients studied in Almazov Medical Center Russian Federation. Blood 128(22):5499 (ASH annual meeting abstracts)Google Scholar
  22. 22.
    Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C et al (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30(2):431–438.  https://doi.org/10.1038/leu.2015.277 CrossRefGoogle Scholar
  23. 23.
    Xu Y, Kwok B, Yung A, Flamholz R, Wu Z, Dabbas B, Reddy P (2015) Clinicopathologic analysis of CALR mutation subtypes in myeloproliferative neoplasms. Blood 126(23):2822 (ASH annual meeting abstracts)Google Scholar
  24. 24.
    Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, Abou Hussein AK, Hanson CA, Ketterling RP, Pardanani A, Tefferi A (2016) Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol 91(5):503–506.  https://doi.org/10.1002/ajh.24338 CrossRefGoogle Scholar
  25. 25.
    Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057–1069.  https://doi.org/10.1038/s41375-018-0077-1 CrossRefGoogle Scholar
  26. 26.
    Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M (2010) A prospective study on 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease tranformation and vascular complications. Leukemia 24(9):1574–1579.  https://doi.org/10.1038/leu.2010.148 CrossRefGoogle Scholar
  27. 27.
    Cassinat B, Verger E, Kiladjian JJ (2014) Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med 371(2):188–189.  https://doi.org/10.1056/NEJMc1401255 CrossRefGoogle Scholar
  28. 28.
    Haslam K, Langabeer SE, Molloy K, McMullin MF, Conneally E (2014) Assessment of CALR mutations in myelofibrosis patients post allogeneic stem cell transplantation. Br J Haematol 166(5):800–802.  https://doi.org/10.1111/bjh.12904 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Massimiliano Bonifacio
    • 1
    Email author
  • Rachele Montemezzi
    • 1
  • Alice Parisi
    • 2
  • Giovanna De Matteis
    • 3
  • Roberta Bertorelle
    • 4
  • Luigi Scaffidi
    • 1
  • Cinzia Candiotto
    • 4
  • Giuseppe Lippi
    • 3
  • Alberto Zamò
    • 5
  • Marco Chilosi
    • 6
  • Giovanni Pizzolo
    • 1
  • Aldo Scarpa
    • 2
  • Mauro Krampera
    • 1
  1. 1.Department of Medicine, Section of HematologyUniversity of VeronaVeronaItaly
  2. 2.Department of Diagnostics and Public Health, Section of Pathological AnatomyUniversity of VeronaVeronaItaly
  3. 3.Department of Diagnostics and Public Health, Section of Clinical BiochemistryUniversity of VeronaVeronaItaly
  4. 4.Immunology and Molecular OncologyVeneto Institute of Oncology IOV-IRCCSPaduaItaly
  5. 5.Department of Oncology, Section of Pathological AnatomyUniversity of TurinTurinItaly
  6. 6.Department of PathologyPederzoli Hospital, Peschiera del GardaVeronaItaly

Personalised recommendations